Penthiopyrad induced the disorders of lipid metabolism via affecting fatty acid synthesis and β-oxidation, in accordance with remarkable changes in the content of triglycerides and cholesterol and the expression of key genes (hmgcrα, pparα1, srebf1, cyp51 and acca1) at 1.2 mg/L.
To elucidate the mechanism, LXRα inhibitor SR9243 and SREBP1 inhibitor fatostatin were used to verify the role of LXRα and SREBP1 in Cu-induced disorder of lipid metabolism.